# The augmentative role of chitosan and platelet-rich fibrin in reducing epidural fibrosis after laminectomy in rats

**Authors:** Samah Fouad, Marwa Abass, Awad Rizk, Esam Mosbah, Mostafa M. Nabeeh, Ayman S. Elmezayyen, M. I. El-Henawey, Adel Zaghloul

PMC · DOI: 10.1186/s40001-025-02951-3 · European Journal of Medical Research · 2025-08-14

## TL;DR

This study shows that combining chitosan and platelet-rich fibrin can reduce scar tissue formation after spinal surgery in rats.

## Contribution

The novel contribution is demonstrating that combining chitosan and PRF reduces epidural fibrosis more effectively than either alone.

## Key findings

- PRF, chitosan, and their combination significantly reduced epidural fibrosis compared to the laminectomy group.
- The combination group showed the greatest reduction in scar tissue and inflammation.
- mRNA analysis revealed decreased TGFβ-1 and IL6 expression in treatment groups.

## Abstract

Epidural fibrosis (EF) is the major complication that develops in the operative region of the spinal vertebrae. This fibrous scar connects the connective tissue around the lateral nerve roots and epidural, resulting in severe pain post-spinal operation and impairment of the nerves’ function.

This study was conducted to investigate the effect of using platelet-rich fibrin (PRF), chitosan, and their combination in reducing epidural fibrosis after laminectomy in rats.

Ninety male Sprague Dawley rats weighing 255 ± 55 g were randomly assigned to five groups, each consisting of 15 rats: the normal group (control), the laminectomy group, the PRF group, the chitosan group, the combination group (PRF/chitosan), and the donor group. All rats, except the control group, had lumbar laminectomy surgeries between L3 and L5. Macroscopic analysis, histological evaluations, and mRNA analysis for TGFβ-1 and IL6 were compared statistically after a 30-day follow-up.

In comparison to the laminectomy group, the EF area was significantly decreased in the PRF, chitosan, and combination groups. Histological study, macroscopic inspection, and mRNA expression of TGFβ-1 (P < 0.0001) and IL6 (P < 0.0001) show that the use of PRF with chitosan topically in dura following laminectomy resulted in a decrease in scar tissue formation, inflammation, and EF post-laminectomy.

The combination of chitosan with PRF is a potential therapeutic approach for minimizing EF in rats after laminectomy.

## Linked entities

- **Proteins:** TGFB1 (transforming growth factor beta 1), IL6 (interleukin 6)
- **Chemicals:** chitosan (PubChem CID 129662530)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Mtpn (myotrophin) [NCBI Gene 79215] {aka Gcdp}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}
- **Diseases:** scar (MESH:D002921), granuloma (MESH:D006099), lumbar spinal stenosis (MESH:C563613), Arachnoiditis (MESH:D001100), disc injury (MESH:D055959), FBSS (MESH:D055111), spinal stenosis (MESH:D013130), back pain (MESH:D001416), nerve root injury (MESH:D011843), Inflammation (MESH:D007249), venous leg ulcers (MESH:D014647), SCI (MESH:D013119), pseudoarthrosis (MESH:D011542), disc herniation (MESH:D007405), EF (MESH:D005355), neuropathic pain (MESH:D009437), spinal instability (MESH:D043171), compression (MESH:D009408), dura damage (MESH:D020263), infection (MESH:D007239), spinal illnesses (MESH:D013122), hemorrhage (MESH:D006470), stenosis (MESH:D003251), diabetic (MESH:D003920), hematoma (MESH:D006406), calcification (MESH:D002114), pain (MESH:D010146), adhesion (MESH:D000267), lower back and/or lower extremity pain (MESH:D017116)
- **Chemicals:** amine (MESH:D000588), hematoxylin (MESH:D006416), Tubastatin A (MESH:C553587), Acetic acid (MESH:D019342), poly-N-acetylglucosamine (MESH:C113579), water (MESH:D014867), ozone (MESH:D010126), Chi (MESH:D048271), Tranexamic acid (MESH:D014148), eosin (MESH:D004801), EDTA (MESH:D004492), paraffin (MESH:D010232), chitin (MESH:D002686), ketamine HCl (MESH:D007649), MT (-), MDA (MESH:D008315), Xylazine HCl (MESH:D014991), Terramycin (MESH:D010118), Ampicillin (MESH:D000667), H&amp;E (MESH:D006371), paraformaldehyde (MESH:C003043), berberine (MESH:D001599), metformin (MESH:D008687), thiopental sodium (MESH:D013874), formaldehyde (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** A 400X

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12351833/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12351833/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12351833/full.md

---
Source: https://tomesphere.com/paper/PMC12351833